← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Arietis
Boston, MA
$27,412,288
Total funding
10
Grants
Funding over time
peak $3.2M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,412,288 · 10
By mechanism
R44$19,267,338 · 6
R01$6,361,593 · 1
R43$1,783,357 · 3
Investigators at Arietis
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of ureadepsipetides for drug-resistant infections$1,529,042
R01 · FY2019 · AI
Bactericidal antibiotic for Vancomycin Resistant Enterococci$1,251,577
R44 · FY2017 · AI
Bactericidal antibiotic for Vancomycin Resistant Enterococci$1,248,159
R44 · FY2018 · AI
Development of ureadepsipetides for drug-resistant infections$1,235,145
R01 · FY2020 · AI
Bactericidal antibiotic for Vancomycin Resistant Enterococci$1,218,307
R44 · FY2016 · AI
Development of ureadepsipetides for drug-resistant infections$1,209,617
R01 · FY2021 · AI
Development of ureadepsipetides for drug-resistant infections$1,200,871
R01 · FY2022 · AI
Development of ureadepsipetides for drug-resistant infections$1,186,918
R01 · FY2023 · AI
Antibiotics for Recalcitrant Infection$1,000,000
R44 · FY2016 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori$1,000,000
R44 · FY2013 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic$1,000,000
R44 · FY2023 · AI
Antibiotics for Recalcitrant Infection$1,000,000
R44 · FY2017 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori$1,000,000
R44 · FY2015 · AI
Antibiotics for Recalcitrant Infection$1,000,000
R44 · FY2015 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic$1,000,000
R44 · FY2025 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori$1,000,000
R44 · FY2014 · AI
Therapy Against Recalcitrant C. albicans Infection$999,998
R44 · FY2011 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic$999,619
R44 · FY2024 · AI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic$996,046
R44 · FY2022 · AI
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic$995,100
R44 · FY2023 · AI